

Technology Advisory Committee A Interests Register

ID3742 Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer

Publication Date: 31/10/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Kate Ren	EAG	Indirect - Financial	Kate is a member of the EAG team critiquing ID3742. After the submission of the EAG report, she provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	29/01/2024	It was agreed that Kate's declaration would not prevent her from being part of the EAG.
Prithwiraj Das	Committee C Member	Indirect - Financial Interests	Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months.	05/02/2024	It was agreed that Prithwiraj's declaration would not prevent him from being part of the committee.
Becky Pennington	Committee A Member	Direct – Financial Interests	Becky received consultancy fees from Roche for methods work, not related to trastuzumab or gastric cancer.	19/10/2023	It was agreed that Becky's declaration would not prevent her from being part of the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Kate Ren	EAG	Indirect - Financial	Kate is a member of the EAG team critiquing ID3742. After the submission of the EAG report, she provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	29/01/2024	It was agreed that Kate's declaration would not prevent her from being part of the EAG.
Prithwiraj Das	Committee C Member	Indirect - Financial Interests	Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months.	05/02/2024	It was agreed that Prithwiraj's declaration would not prevent him from being part of the committee.
Dr Patrick De Barr	Committee A Member	Direct – financial interests	Patrick received paid employment from a company who have a PD1 antibody under development, however this is in a different indication.	25/01/2024	It was agreed that Patrick's declaration would not prevent him from being part of the committee.
			Patrick received paid employment from a company (Incyte) who are developing a monoclonal antibody against PD1. This is in a different lead indication to the appraisals (ID1688 and ID3742).	24/10/2023	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Kate Ren	EAG	Indirect - Financial	Kate is a member of the EAG team critiquing ID3742. After the submission of the EAG report, she provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	29/01/2024	It was agreed that Kate's declaration would not prevent her from being part of the EAG.
Prithwiraj Das	Committee C Member	Indirect - Financial Interests	Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months.	05/02/2024	It was agreed that Prithwiraj's declaration would not prevent him from being part of the committee.
Was Mansoor	Clinical Expert	Direct – professional and financial	<ul style="list-style-type: none"> Has had advisory roles with Ipsen, Novartis, Pfizer, MSD, BMS. Speaker's bureau for Ipsen, Novartis, MSD and Servier. Travel grants from MSD, Ipsen, MSD, Servier. Institutional grants with Nordic and BMS 	07/11/2023	It was agreed that Was' declaration would not prevent him from providing expert advice to the committee.
Elizabeth Smythe	Clinical expert	Direct – financial	<ul style="list-style-type: none"> I have previously received financial remuneration and/or travel support for meetings from the following companies: Astellas, Astra 	29/03/2023	It was agreed that Elizabeth's declaration would not prevent her from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Kate Ren	EAG	Indirect - Financial	Kate is a member of the EAG team critiquing ID3742. After the submission of the EAG report, she provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	29/01/2024	It was agreed that Kate's declaration would not prevent her from being part of the EAG.
Prithwiraj Das	Committee C Member	Indirect - Financial Interests	Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months.	05/02/2024	It was agreed that Prithwiraj's declaration would not prevent him from being part of the committee.
			<p>Zeneca, BMS, Celgene, Daiichi Sankyo, Everest Research, Five Prime, Gritstone, Merck, Novartis, Roche, Pfizer, Servier, Viracta, and Zymeworks</p> <ul style="list-style-type: none"> I am the chief investigator of a trial which is managed by Southampton CTU which has been funded by BMS. I am the chief investigator of a trial which is managed by Southampton CTU which has been funded by Astra Zeneca 		providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Kate Ren	EAG	Indirect - Financial	Kate is a member of the EAG team critiquing ID3742. After the submission of the EAG report, she provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	29/01/2024	It was agreed that Kate's declaration would not prevent her from being part of the EAG.
Prithwiraj Das	Committee C Member	Indirect - Financial Interests	Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months.	05/02/2024	It was agreed that Prithwiraj's declaration would not prevent him from being part of the committee.
			<ul style="list-style-type: none"> My current institution (Cambridge) receives funding (either directly or through contract research organisations) for trials on which I am the principal investigator from Astellas, Astra Zeneca, Basilea, Daiichi Sankyo, MSD, Novartis and Roche. 		
Elizabeth Smythe	Clinical expert	Direct – non-financial	<ul style="list-style-type: none"> I am the co-chair of the EORTC (European Organisation for Research and Treatment of Cancer) Gastric Cancer Taskforce I am a member of the ESMO Guidelines Committee and Senior 		It was agreed that Elizabeth's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Kate Ren	EAG	Indirect - Financial	Kate is a member of the EAG team critiquing ID3742. After the submission of the EAG report, she provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	29/01/2024	It was agreed that Kate's declaration would not prevent her from being part of the EAG.
Prithwiraj Das	Committee C Member	Indirect - Financial Interests	Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months.	05/02/2024	It was agreed that Prithwiraj's declaration would not prevent him from being part of the committee.
			<p>author of the Gastric and Oesophageal guidelines.</p> <ul style="list-style-type: none"> I am a founder member of the United Kingdom and Ireland Oesophagogastric Group (UKIOG) which has received support from MSD (not directly to me but to the organisation). 		